Profile data is unavailable for this security.
About the company
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
- Revenue in CHF (TTM)0.00
- Net income in CHF-19.62m
- Incorporated1996
- Employees50.00
- LocationSpexis AGHegenheimermattweg 125ALLSCHWIL 4123SwitzerlandCHE
- Phone+41 615671600
- Fax+41 615671601
- Websitehttps://spexisbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lidds AB | 0.00 | -2.61m | 1.58m | 2.00 | -- | 1.82 | -- | -- | -0.5546 | -0.5546 | 0.00 | 0.0746 | 0.00 | -- | -- | 0.00 | -95.41 | -46.33 | -110.09 | -51.61 | -- | -1,934.24 | -- | -3,076.68 | -- | -- | 0.0812 | -- | -100.00 | -- | -9.08 | -- | -- | -- |
| N4 Pharma PLC | 2.22k | -1.46m | 1.61m | 5.00 | -- | 1.25 | -- | 723.64 | -0.0053 | -0.0053 | 0.00001 | 0.0042 | 0.0011 | -- | 0.009 | 390.00 | -74.20 | -57.05 | -79.41 | -61.13 | -- | -- | -65,475.90 | -309,312.80 | -- | -- | 0.00 | -- | -- | -51.52 | -24.05 | -- | -- | -- |
| Aptahem AB | 2.73k | -966.08k | 1.64m | -- | -- | 0.3066 | -- | 601.91 | -0.0426 | -0.0426 | 0.0001 | 0.1109 | 0.0005 | -- | 0.10 | -- | -17.54 | -39.26 | -18.94 | -44.19 | 4,464.22 | -- | -35,390.22 | -- | -- | -8.44 | 0.00 | -- | -- | -- | -25.36 | -- | -- | -- |
| Private Rented Sector SA | 44.15k | 6.01k | 1.69m | -- | 281.69 | -- | 81.73 | 38.32 | 0.0206 | 0.0206 | 0.1514 | -0.035 | 1.79 | -- | 2.20 | -- | 24.28 | 1,266.23 | -- | -- | 23.89 | -1,935.55 | 13.60 | 2,755.44 | -- | -- | -- | -- | -- | -- | -66.26 | -- | -- | -- |
| Nuformix PLC | 0.00 | -498.43k | 1.89m | 2.00 | -- | 0.3584 | -- | -- | -0.0006 | -0.0006 | 0.00 | 0.0056 | 0.00 | -- | -- | -- | -9.50 | -- | -9.95 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| ReNeuron Group Plc | 284.04k | -5.79m | 2.20m | 34.00 | -- | 0.7966 | -- | 7.75 | -0.0888 | -0.0888 | 0.0044 | 0.0424 | 0.0246 | -- | 0.6442 | 7,323.53 | -50.10 | -43.12 | -101.09 | -58.50 | -- | -- | -2,037.35 | -714.73 | -- | -- | 0.1247 | -- | 31.51 | 65.26 | 44.18 | -- | -1.31 | -- |
| Inno-Gene SA | 104.64k | -301.32k | 2.24m | 27.00 | -- | 1.73 | -- | 21.41 | -0.2363 | -0.2363 | 0.0814 | 1.03 | 0.0502 | 2.04 | 0.5807 | -- | -14.47 | 7.92 | -18.94 | 10.73 | -41.03 | 73.63 | -287.96 | 11.59 | 2.20 | -- | 0.0635 | -- | -93.08 | -16.73 | -542.12 | -- | -- | -- |
| Cyxone AB | 0.00 | -1.85m | 2.28m | 1.00 | -- | 0.7806 | -- | -- | -0.1747 | -0.1747 | 0.00 | 0.1589 | 0.00 | -- | -- | 0.00 | -50.57 | -66.19 | -57.08 | -72.35 | -- | -- | -- | -- | -- | -- | 0.0042 | -- | -- | -- | 45.87 | -- | -13.31 | -- |
| Hellenic Dynamics PLC | -114.07bn | -114.07bn | 2.36m | 25.00 | -- | 2.40 | -- | -- | -- | -- | -- | 0.006 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.3029 | -- | -- | -- | -- | -- | -- | -- |
| Circio Holding ASA | 10.32k | -9.29m | 2.41m | 11.00 | -- | -- | -- | 233.89 | -16.75 | -16.75 | 0.0181 | -12.89 | 0.0019 | -- | 0.0072 | 11,181.82 | -172.29 | -46.58 | -- | -53.40 | -- | -- | -90,029.27 | -6,902.00 | -- | -9.82 | 7.73 | -- | -98.77 | 35.43 | 74.42 | -- | -- | -- |
| Spexis AG | 0.00 | -19.62m | 2.44m | 50.00 | -- | -- | -- | -- | -0.3597 | -0.3597 | 0.00 | -0.0546 | 0.00 | -- | -- | 0.00 | -84.79 | -53.28 | -149.58 | -68.93 | -- | -- | -- | -1,117.43 | -- | -- | 1.69 | -- | -- | -- | -5.75 | -- | -- | -- |
| Biophytis SA | 0.00 | -16.34m | 2.45m | 26.00 | -- | -- | -- | -- | -6.55 | -6.55 | 0.00 | -1.48 | 0.00 | -- | -- | -- | -100.31 | -97.52 | -1,481.81 | -487.25 | -- | -- | -- | -- | -- | -12.25 | -- | -- | -- | -- | 29.69 | -- | 14.25 | -- |
| bioXXmed AG | 19.69k | -634.13k | 2.49m | 1.00 | -- | 0.1229 | -- | 126.50 | -0.1286 | -0.1286 | 0.004 | 4.11 | 0.0009 | -- | 0.4423 | 20,510.00 | -3.02 | -10.26 | -3.06 | -10.75 | -- | -- | -3,221.36 | -7,303.55 | -- | -- | 0.00 | -- | -72.60 | -32.89 | 79.56 | -- | -- | -- |
| Gabather AB | 0.00 | -903.05k | 2.60m | -- | -- | -- | -- | -- | -0.6814 | -0.6814 | 0.00 | -0.1489 | 0.00 | -- | -- | -- | -144.39 | -56.57 | -1,110.23 | -67.36 | -- | -- | -- | -17,298,800.00 | -- | -- | -- | -- | -- | -- | -10.40 | -- | -- | -- |
| CRISM' Therapeutics Corp | 0.00 | -2.13m | 2.69m | 4.00 | -- | 0.195 | -- | -- | -0.2148 | -0.8667 | 0.00 | 0.3702 | 0.00 | -- | -- | 0.00 | -14.26 | -8.67 | -14.89 | -9.02 | -- | -- | -- | -- | -- | -3.51 | 0.00 | -- | -- | -- | 8.21 | -- | -- | -- |
| Lipigon Pharmaceuticals AB | 1.40m | -1.08m | 3.11m | -- | -- | 1.70 | -- | 2.22 | -0.2459 | -0.2459 | 0.2138 | 0.1694 | 1.07 | -- | 21.49 | -- | -83.21 | -314.67 | -137.73 | -426.49 | -- | -- | -77.44 | -488.14 | -- | -- | 0.00 | -- | -- | 444.44 | 67.83 | -- | -- | -- |
Data as of Jun 13 2024. Currency figures normalised to Spexis AG's reporting currency: Swiss Franc CHF
0.99%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Credit Suisse Asset Management (Schweiz) AGas of 29 Feb 2024 | 405.18k | 0.60% |
| UBS Asset Management Switzerland AGas of 07 May 2024 | 121.14k | 0.18% |
| Z�rcher Kantonalbank (Investment Management)as of 30 Apr 2024 | 77.22k | 0.11% |
| Credit Suisse AGas of 31 Jan 2024 | 25.45k | 0.04% |
| BlackRock Asset Management Schweiz AGas of 08 May 2024 | 18.76k | 0.03% |
| Pictet Asset Management SAas of 29 Feb 2024 | 18.33k | 0.03% |
| LLB Asset Management AGas of 30 Apr 2024 | 2.35k | 0.00% |
| State Street Global Advisors France SAas of 31 Mar 2024 | 1.50k | 0.00% |
More ▼
Data from 31 Mar 2024 - 06 Jun 2024Source: FactSet Research Systems Inc.
